Uncategorized

ORPHELIA Pharma and Clinigen sign an exclusive agreement to supply Kigabeq® (vigabatrin)

Newsletter July 2021

Over the past six months, the Foundation and Institute have supported 9 projects that we present to you in this 11th newsletter.

One new project supported by our Foundation Dominique & Tom Alberici

During the Board of Directors in June 2021, our Corporate Foundation supported one new project: the financing of a weekend of hiking for the Clubhouse Lyon.

ORPHELIA Pharma and Gustave Roussy announce issuance of European Patent covering Kimozo®, the first oral liquid formulation of temozolomide

ORPHELIA Pharma announces the inclusion of the first patient in the TEMOkids pediatric clinical trial

Two new projects supported by our Foundation and our Endowment Fund

During the Board of Directors in March 2021, our Corporate Foundation and our Endowment Fund supported 2 new projects: the financing of various material for the Matokisa school set up in Madagascar by parents of disabled children and the financing of the photo book made by disabled children about the Berry Canal with the association PEP18.

ORPHELIA Pharma and Biocodex sign a license agreement for the distribution of Kigabeq® in 14 european countries

ORPHELIA Pharma opens its operating pharmaceutical establishment in France

AACR annual meeting 2021

Jeremy BASTID, CEO of OREGA Biotech, will participate to the upcoming AACR annual meeting to be held virtually on April 10-15 and May 17-21, 2021.

ORPHELIA Pharma awarded a grant from the region Île-de-France to support business activity development in Europe and in the US